Skip to content

Survey of Abnormality Rates of 10 Renal Injury Biomarkers in Urine Routine Test Samples from Patients with Malignant Tumors in a Tumor-Specialized Hospital

Survey of Abnormality Rates of 10 Renal Injury Biomarkers in Urine Routine Test Samples from Patients with Malignant Tumors in a Tumor-Specialized Hospital

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122505
Enrollment
Unknown
Registered
2026-04-14
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease (CKD)

Interventions

Sponsors

Beijing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Tumor patients: 1. Tumor patients whose urine samples were sent for routine urine tests; 2. Those who had previously signed the informed consent form for clinical trials research; 3. Patients diagnosed with cancer through physical examination, imaging tests, biopsy and/or postoperative pathological tissue examination; Healthy employees for physical examination: Signed informed consent form + Questionnaire.

Exclusion criteria

Exclusion criteria: Tumor patients: Those with incomplete clinical information. Healthy individuals: 1. Those undergoing physical examinations refused to participate in this study, did not sign the informed consent form or fill out the health questionnaire; 2. Have diabetes, hypertension, high uric acid, positive urine albumin, autoimmune diseases, malignant tumors, etc.

Design outcomes

Primary

MeasureTime frame
Positive rates of 10 urinary specific proteins in the diagnosis of early renal injury in cancer patients;

Countries

China

Contacts

Public ContactLiu Xia

Beijing Cancer Hospital

lxia1991@126.com+86 10 8819 6075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026